We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PNH

News List

Ra Pharma files $100M round as Soliris rival clears phase 2 trial fiercebiotech
December 27, 2018
Armed with a phase 2 win for its lead drug zilucoplan in rare disease myasthenia gravis (MG), Ra Pharma has pressed the button on a public funding round that it hopes could raise up to $115 million......
FDA Approves New Treatment for Paroxysmal Nocturnal Hemoglobinuria americanpharmaceuticalreview
December 27, 2018
The U.S. Food and Drug Administration (FDA) approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.....
FDA Approves Ultomiris (ravulizumab-cwvz) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs
December 26, 2018
Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz).....

Previous page 1 2 Next page